双特异性超越 Keytruda

IF 33.1 1区 生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Nature biotechnology Pub Date : 2024-10-14 DOI:10.1038/s41587-024-02451-5
{"title":"双特异性超越 Keytruda","authors":"","doi":"10.1038/s41587-024-02451-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":null,"pages":null},"PeriodicalIF":33.1000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bispecific upstages Keytruda\",\"authors\":\"\",\"doi\":\"10.1038/s41587-024-02451-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19084,\"journal\":{\"name\":\"Nature biotechnology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":33.1000,\"publicationDate\":\"2024-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.nature.com/articles/s41587-024-02451-5\",\"RegionNum\":1,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.nature.com/articles/s41587-024-02451-5","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

在一项非小细胞肺癌头对头临床试验中,新型双特异性药物 ivonescimab 的疗效优于默克公司的大片 PD-1 检查点抑制剂 Keytruda(pembrolizumab)。Summit Therapeutics 公司在今年 9 月于圣地亚哥举行的世界肺癌大会上公布的 3 期临床数据显示,VEGF-PD-1 双效抗体的无进展生存期比 PD-1 阻断剂提高了近一倍。接受 ivonescimab 治疗的患者无进展生存期的中位数为 11 个月,而接受 Keytruda 单药治疗的患者只有 5.8 个月。从400名患者中得出的这些结果比预期的要好,但这只是一项仅在中国进行的试验,不太可能支持美国食品药品管理局的申请。Ivonescimab是一种人源化四价双特异性抗体,可同时靶向PD-1和血管内皮生长因子(VEGF)。将 PD-1 抑制剂与阻断肿瘤血管生成相结合以阻止肿瘤免疫抑制的原理并不新颖,但血管内皮生长因子抑制剂可导致严重出血,而检查点抑制剂则与免疫相关毒性有关。通过在单个抗体上同时存在两个结合域,ivonescimab能够避免这些副作用,虽然它也有一些与血管内皮生长因子相关的不良反应,如高血压,但出血风险并没有增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Bispecific upstages Keytruda
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nature biotechnology
Nature biotechnology 工程技术-生物工程与应用微生物
CiteScore
63.00
自引率
1.70%
发文量
382
审稿时长
3 months
期刊介绍: Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research. The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field. Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology. In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.
期刊最新文献
Amyloid is everywhere, but new treatments could stop the toxic build up Italy tests first gene-edited vines for winemaking Ancient and versatile CRISPR–Cas nuclease created with ancestral sequence reconstruction CRISPR Nobelists surrender their own European patents What will it take to get miRNA therapies to market?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1